论文部分内容阅读
目的探讨替罗非班对急性STEMI经PCI治疗后的临床预后效果。方法将我院自2016年3月~2017年3月收治的确诊为STEMI患者共82例作为研究对象,随机分为观察组和对照组。两组均口服阿司匹林和氯吡格雷,观察组于动脉穿刺前进行10μg/kg替罗非班静脉注射,维持24h静脉滴注,PCI术前静脉注射肝素,对照组则不进行替罗非班注射。评价两组患者术后的心肌呈色和ST段回落情况。结果术后观察组心肌呈色Ⅲ级率达到70.73%,显著高于对照组(39.02%);ST段完全回落比为60.98%,显著高于对照组(29.27%),P<0.05,差异具有统计学意义。结论替罗非班对改善PCI术后心肌灌注指标,恢复心功能方面疗效显著,值得临床推广。
Objective To investigate the clinical effect of tirofiban on acute STEMI after PCI. Methods A total of 82 STEMI patients admitted from March 2016 to March 2017 in our hospital were randomly divided into observation group and control group. Both groups were given aspirin and clopidogrel orally. The observation group was given intravenous injection of tirofiban 10 μg / kg intravenously before arterial puncture for 24 h, intravenous injection of heparin before PCI, and no tirofiban injection for the control group . The postoperative myocardial colorimetry and ST segment regression were evaluated in both groups. Results The myocardial grade III of the postoperative observation group was 70.73%, significantly higher than that of the control group (39.02%). The complete regression rate of ST segment was 60.98%, significantly higher than that of the control group (29.27%), P <0.05, Statistical significance. Conclusion Tirofiban has significant curative effect in improving myocardial perfusion index and recovering cardiac function after PCI, which is worthy of clinical promotion.